In recent years, the TET2 mutation has been found to play an important role in the pathogenesis of myeloid sarcoma21; Furthermore, animal experiments and clinical observations have suggested that decitabine is safe and effective in treating patients with myeloid sarcoma with the TET2 mutation. Here, TET2 is linked to myeloid sarcoma.